• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Recognized Consensus Standards

  • Print
  • Share
  • E-mail
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC

New Search Back To Search Results
Part B: Supplementary Information Sheet (SIS)
FR Recognition List Number 040 Date of Entry 08/14/2015 
FR Recognition Number 8-388
ISO 6474-2 First edition 2012-04-15
Implants for surgery - Ceramic materials - Part 2: Composite materials based on a high-purity alumina matrix with zirconia reinforcement
This part of ISO 6474 specifies the characteristics of, and corresponding test methods for, a biocompatible and biostable ceramic-bone-substitute material based on a zirconia-reinforced, high-purity alumina matrix composite for use as a component in orthopaedic joint prostheses.

This part of ISO 6474 is intended for composite materials which are based on an alumina matrix, i.e. alumina as the dominating phase in the composite with a mass fraction of > 60 %, similar to the material described in ISO 6474-1, but extended by means of a certain amount of zirconia and other defined ingredients.

NOTE The required properties in this part of ISO 6474 differ from those in ISO 6474-1 with respect to strength and fracture toughness. Furthermore, there are requirements specifically applicable for zirconia-containing materials (see ISO 13356).

In the material composition as defined in this part of ISO 6474, additional additives are listed. Typical additives for alumina or zirconia ceramics are Mg, Y, Ce and others. Such additives can be useful in order to improve the mechanical properties and/or the chemical stability of the alumina-zirconia composite material. This part of ISO 6474 does not cover the biocompatibility (see ISO 10993-1) of these inorganic additives in the human body. It is the responsibility of the manufacturer to evaluate the biocompatibility of the specific ceramic composite material which is produced within the framework of this part of ISO 6474.
Extent of Recognition
Complete standard
Rationale for Recognition
This standard is relevant to medical devices and is recognized on its scientific and technical merit and/or because it supports existing regulatory policies.
Transition Period
FDA recognition of ISO 6474-2 First edition 2012-04-15 [Rec# 8-388] will be superseded by recognition of ISO 6474-2 Second edition 2019-03 [Rec# 8-505]. FDA will accept declarations of conformity, in support of premarket submissions, to [Rec# 8-388] until July 24, 2022 After this transition period, declarations of conformity to [Rec# 8-388] will not be accepted.
Standards Development Organization
ISO International Organization for Standardization https://www.iso.org/
FDA Specialty Task Group (STG)